In this episode, Dr. Sarah Samreen and Dr. Andrea Stark discuss the Medicare GLP-1 Bridge program, a new federal program that may expand access to certain GLP-1 medications for eligible Medicare Part D patients being treated for obesity.
Beginning July 1, 2026, eligible participants may have access to medications including Zepbound, injectable Wegovy, oral Wegovy, and Foundayo, the newest oral GLP-1medication.
For eligible patients, the monthly copay may be $50, which Dr. Stark described as a significant shift compared with the higher out-of-pocket costs many patients have faced for these medications.
A new option for obesity treatment
Drs. Samreen and Stark emphasized that Medicare Bridge is specifically related to the treatment of obesity.
“This is a landmark change in the treatment and recognition of obesity as a chronic disease,” Dr. Stark said.
The program is especially meaningful because it may help more patients access medications that were previously difficult to afford. As Dr. Stark noted, some patients have paid hundreds of dollars each month for these medications.
The doctors also discussed why this change may matter beyond Medicare. Increased access through a federal program could eventually influence broader insurance coverage trends, though they noted that any impact on commercial insurance would not happen immediately.
Eligibility depends on several factors
The doctors explained that the program is not available to every Medicare patient. Eligibility depends on specific criteria, including BMI and certain medical conditions.
Patients with a BMI of 35 or higher may qualify based on BMI alone. Patients with lower BMIs may need to meet additional criteria related to comorbidities, such as certain cardiovascular risk factors, prediabetes, or other qualifying medical conditions.
Because the criteria can be nuanced, Dr. Stark encouraged patients to talk with a physician rather than trying to determine eligibility on their own.
“These are the nuances where you really probably need to see your physician and discuss these medications and see if you have eligibility,” Dr. Stark said.
In some cases, patients may need additional lab work or imaging tests to determine whether they meet the criteria.
Some patients may be excluded
The doctors also discussed exceptions. Some Medicare Part D patients may not be eligible for the Bridge Program if they already have access to GLP-1 medications through existing coverage for another condition.
For example, patients who already have coverage for Wegovy because of cardiovascular disease or Zepbound because of moderate or severe sleep apnea, may not be eligible for the Bridge program. Patients who already have coverage for diabetes medications such as Ozempic or Mounjaro may also be excluded.
Dr. Stark noted that this may not change access for every patient, but it could still help a large number of people.
Why a weight management visit can help
Drs. Samreen and Stark encouraged patients who think they may qualify to contact UTMB Pharmacy Services at 832-505-3170. They can help verify your coverage, determine eligibility, and connect you with a weight management physician.
Through the weight management clinic, patients receive support beyond medication management, including care from medical weight loss specialists, dietitians, counselors, and bariatric surgeons when needed.
The doctors emphasized that obesity treatment is highly individualized, and the best approach depends on the patient’s medical history, goals, eligibility, coverage, and long-term needs.
How UTMB Pharmacy can support patients
The episode also highlighted UTMB Pharmacy as an important resource for patients navigating access to GLP-1 medications.
Dr. Stark said she had been preparing patients for the rollout and had prescriptions ready at UTMB Pharmacy for July 1 fill dates. She also described UTMB Pharmacy as a valuable resource for prior authorizations, approvals, communication through MyChart, and efficient delivery.
For patients who are unsure where to start or who have questions about meeting Medicare Bridge program criteria, the doctors encouraged them to seek care rather than trying to navigate the process alone.
Final takeaway
The Medicare GLP-1 Bridge program may represent an important step forward in improving access to obesity treatment for eligible Medicare Part D patients.
While the criteria are specific and not every patient will qualify, the program may make GLP-1 medications more affordable for many patients who previously faced high out-of-pocket costs.
For patients considering weight loss treatment or wondering whether they may qualify, the next step is to contact UTMB Pharmacy Services at 832-505-3170. They can help verify your coverage, determine eligibility, and guide you through the approval process.
As Drs. Samreen and Stark explained, this is a significant moment in obesity care, and UTMB Health is ready to help patients understand their options.